(P112) Once-Weekly Basal Insulin Efsitora Alfa Demonstrates Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With T2D: Results from Phase 2

This poster discusses Efsitora alfa, a once-weekly basal insulin, a selective insulin receptor agonist that combines a single-chain variant of insulin with a human immunoglobulin G2 (IgG2) Fc domain. This novel approach allows for efsitora’s pharmacokinetic profile to be flat from peak-to-trough in individuals with diabetes. In a phase 2 study, Efsitora alfa demonstrates non-inferiority to insulin degludec in hemoglobin A1c from baseline to week 26.